Lecanemab Drug – medicarereport.org

Thursday, November 21, 2024

Latest:

Aging Alzheimer's/Dementia FDA Part D/Prescription Drugs

Eileen Cook January 11, 2024January 11, 2024 Alzheimer's Disease, beta amyloid plaques, blood test, Dementia, FDA, Lecanemab Drug, Older Adults

Blood tests can help diagnose Alzheimer’s — if they’re accurate enough. Not all are

(By Jon Hamilton for NPR) A new generation of blood tests is poised to change the way doctors determine whether

Alzheimer's/Dementia FDA Medicare - General Part D/Prescription Drugs

Eileen Cook November 28, 2023November 28, 2023 Aducanumab, Alzheimer's Disease, ARIA, CMS, Dementia, Donanemab, FDA, Lecanemab Drug, medicare, Medicare Part D, Older Adults

Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect

(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover

Alzheimer's/Dementia Health Care Finance Medicaid Medicare - General Part D/Prescription Drugs

Eileen Cook August 2, 2023August 2, 2023 0 Comments Alzheimer's Disease, CMS, Donanemab, Dual Eligible, FDA, Lecanemab Drug, Medicaid, medicare, Medicare Part D, Older Adults

The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers

(By Arthur Allen for KFF Health News) The first drug purporting to slow the advance of Alzheimer’s disease is likely

Aging Alzheimer's/Dementia CMS FDA Health Care Finance Part D/Prescription Drugs

Eileen Cook July 11, 2023July 11, 2023 0 Comments Alzheimer's Disease, CMS, Healthcare Costs, Lecanemab Drug, medicare, Medicare Part D, Older Adults

Leqembi could cost Medicare up to $17.8B

(By Rylee Wilson for Becker’s Hospital Review) Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease, will

Alzheimer's/Dementia CMS FDA Part D/Prescription Drugs

Eileen Cook July 10, 2023July 10, 2023 0 Comments Alzheimer's Disease, CMS, FDA, Lecanemab Drug, Medicare Part D

Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval

(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following

Alzheimer's/Dementia CMS FDA Medicare - General Part D/Prescription Drugs

Eileen Cook June 26, 2023June 26, 2023 0 Comments Aducanumab, Alzheimer's Disease, CMS, FDA, Lecanemab Drug, medicare, Older Adults

An Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why

(By Jon Hamilton for NPR) The first drug shown to slow down Alzheimer’s disease is likely to receive full approval

Alzheimer's/Dementia FDA Health Care Finance Medicare - General Part D/Prescription Drugs

Eileen Cook May 19, 2023May 19, 2023 0 Comments Alzheimer's Disease, FDA, Healthcare Finance, Lecanemab Drug, medicare

New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare

(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published May 18, 2023) The FDA’s accelerated approval of Aduhelm

Alzheimer's/Dementia FDA

Eileen Cook January 9, 2023January 9, 2023 0 Comments Alzheimer's Disease, FDA, Lecanemab Drug

FDA approves Alzheimer’s drug that appears to modestly slow disease

(By Jon Hamilton for NPR) The Food and Drug Administration has approved a drug that may help people in the

Aging Alzheimer's/Dementia Part D/Prescription Drugs

Eileen Cook November 30, 2022November 30, 2022 0 Comments Alzheimer's Disease, Lecanemab Drug

Study: Alzheimer’s drug shows modest success slowing declines in memory, thinking

(By Jon Hamilton for NPR) An experimental drug that removes a substance called amyloid from the brain appears to slow

Alzheimer's/Dementia Part D/Prescription Drugs

Eileen Cook October 20, 2022October 20, 2022 0 Comments Alzheimer's Disease, Lecanemab Drug

‘Front of the line’: For Alzheimer’s patients in successful trial, a feeling of gratitude

(By Andrew Joseph for STAT) When the news came out last month that an experimental Alzheimer’s therapy succeeded in a